verapamil has been researched along with cisapride in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 12 (38.71) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Chen, XL; Hendrix, J; Kang, J; Korolev, AM; Lysenkova, LN; Miroshnikova, OV; Pearlstein, RA; Preobrazhenskaya, M; Rampe, D; Shchekotikhin, AE; Vaz, RJ | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Sen, S; Sinha, N | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Dormehl, IC; du Plessis, M; Maree, M; Meyer, BJ; Pilloy, W | 1 |
| Chen, SA; Chen, YJ; Chiou, CW; Hsiao, CJ; Hsieh, MH; Lee, SH; Yu, WC | 1 |
| Avery, MJ; DePasquale, MJ; Fossa, AA; Leishman, DJ; Raunig, DL | 1 |
| Armelao, L; Cristoni, S; Gross, S; Seraglia, R; Tondello, E; Traldi, P | 1 |
| Avery, M; Fermini, B; Fossa, AA; Raunig, DL; Wang, E; Wisialowski, T; Wolfgang, E | 1 |
| Hamlin, RL; Keene, BW; Kijtawornrat, A; Nishijima, Y; Roche, BM | 1 |
| Hreiche, R; Morissette, P; Turgeon, J | 1 |
| Alderton, W; Berghmans, S; Butler, P; Chassaing, H; Fleming, A; Gardner, I; Golder, Z; Richards, F | 1 |
| Fujii, M; Imaizumi, Y; Ohya, S; Yamamura, H | 1 |
| Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC | 1 |
| Charrez, B; Edwards, AG; Healy, KE; Huebsch, N; Jæger, KH; Tveito, A; Wall, S | 1 |
| Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y | 1 |
| Christini, DJ; Clark, AP; Kalola, D; Krogh-Madsen, T; Wei, S | 1 |
31 other study(ies) available for verapamil and cisapride
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Topics: Amino Acids, Aromatic; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Structural Homology, Protein; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
The detection and evaluation of drug-induced changes in the gastrointestinal motility of beagle dogs using a 111In-labelled resin mixed into a standard meal as tracer.
Topics: Animal Feed; Animals; Cisapride; Dogs; Gastric Emptying; Gastrointestinal Motility; Indium; Male; Methods; Microspheres; Piperidines; Polystyrenes; Radioisotopes; Time Factors; Verapamil | 1985 |
Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cisapride; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Estradiol; Female; Heart Atria; Heart Conduction System; Heart Rate; Sex Characteristics; Torsades de Pointes; Verapamil | 1999 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart Rate; Long QT Syndrome; Male; Piperidines; Pyridines; Terfenadine; Verapamil | 2002 |
Matrix-assisted laser desorption/ionisation mass spectrometry in the study of polycondensation of Ti(OBun)4 in the presence of Si(OEt)4.
Topics: Algorithms; Biotransformation; Chromatography, High Pressure Liquid; Cisapride; Flunarizine; Humans; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Pharmaceutical Preparations; Pharmacokinetics; Propranolol; Verapamil | 2003 |
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
Topics: Animals; Antipsychotic Agents; Bepridil; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Cisapride; Delayed Rectifier Potassium Channels; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Guinea Pigs; Heart Rate; Histamine H1 Antagonists; Humans; In Vitro Techniques; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Piperidines; Potassium Channels, Voltage-Gated; Pyridines; Risperidone; Terfenadine; Verapamil | 2004 |
Use of a failing rabbit heart as a model to predict torsadogenicity.
Topics: Amiodarone; Animals; Cardiac Output, Low; Cisapride; Dose-Response Relationship, Drug; Electrocardiography; Models, Animal; Phenethylamines; Quaternary Ammonium Compounds; Quinidine; Rabbits; Sulfonamides; Torsades de Pointes; Verapamil | 2006 |
Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Cells, Cultured; Cisapride; Dose-Response Relationship, Drug; Drug Synergism; Guinea Pigs; Heart Conduction System; Long QT Syndrome; Male; Myocytes, Cardiac; Potassium Channel Blockers; Time Factors; Verapamil | 2006 |
Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae.
Topics: Animals; Chlorpromazine; Cisapride; Cytochrome P-450 Enzyme System; Larva; Pharmaceutical Preparations; Pharmacokinetics; Substrate Specificity; Verapamil; Zebrafish | 2010 |
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Topics: Action Potentials; Biological Assay; Cell Line; Cisapride; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; HEK293 Cells; High-Throughput Screening Assays; Humans; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Pyridines; Pyrimidinones; Sodium Channels; Terfenadine; Transfection; Verapamil | 2012 |
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentiation; Cell Line; Cell Size; Cisapride; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Embryoid Bodies; Embryonic Stem Cells; Gene Expression Profiling; Genetic Predisposition to Disease; HEK293 Cells; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; Ion Channels; Kidney; Long QT Syndrome; Myocytes, Cardiac; Myofibrils; Nicorandil; Patch-Clamp Techniques; Quinazolines; Verapamil | 2013 |
Inversion and computational maturation of drug response using human stem cell derived cardiomyocytes in microphysiological systems.
Topics: Anti-Ulcer Agents; Calcium Channel Blockers; Cells, Cultured; Cisapride; Computer Simulation; Electrophysiological Phenomena; Humans; Myocytes, Cardiac; Verapamil | 2018 |
Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model.
Topics: Animals; Atrioventricular Block; Bepridil; Cisapride; Computer Simulation; Macaca fascicularis; Sotalol; Torsades de Pointes; Verapamil | 2021 |
An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms.
Topics: Action Potentials; Arrhythmias, Cardiac; Cardiotoxicity; Cisapride; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Ion Channels; Myocytes, Cardiac; Quinidine; Quinine; Verapamil | 2022 |